Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Siu, Michelle K Y ^a   Kong, Daniel S H ^a   Chan, Hoi Yan ^a   Wong, Esther S Y ^a   Ip, Philip P C ^a   Jiang, LiLi ^a   Ngan, Hextan Y S ^a   Le, Xiao Feng ^b   Cheung, Annie N Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLATE RECEPTOR 1; FOLIC ACID; MESSENGER RNA; REDUCED FOLATE CARRIER; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; FOLATE RECEPTOR 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; OVARY; PROMOTER REGIONS, GENETIC; REDUCED FOLATE CARRIER PROTEIN; RNA, MESSENGER; UP-REGULATION; YOUNG ADULT;

EID: 84868697449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047201     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
2. Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, et al. (2003) Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer 97: 2676-2685.
3. Marugame T, Hirabayashi Y, (2007) Comparison of time trends in ovary cancer incidence (1973-1997) in East Asia, Europe, and the USA, from Cancer Incidence in Five Continents Vols IV VIII. Jpn J Clin Oncol 37: 802-803.
4. The Hong Kong Cancer Registry (2007) Department of Health Annual Report. Hong Kong, Department of Health, Hospital Authority.
5. Woodside JV, McCall D, McGartland C, Young IS, (2005) Micronutrients: dietary intake v. supplement use. Proc Nutr Soc 64: 543-553.
6. Larsson SC, Giovannucci E, Wolk A, (2004) Dietary Folate Intake and Incidence of Ovarian Cancer: The Swedish Mammography Cohort. J Natl Cancer Inst 96: 396-402.
7. Kelemen LE, Sellers TA, Vierkant RA, Harnack L, Cerhan JR, (2004) Association of folate and alcohol with risk of ovarian cancer in a prospective study of postmenopausal women. Cancer Causes Control 15: 1085-1093.
8. Kelemen LE, Sellers TA, Keeney GL, Lingle WL, (2005) Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 2168-2172.
9. Pelucchi C, Mereghetti M, Talamini R, Negri E, Montella M, et al. (2005) Dietary folate, alcohol consumption, and risk of ovarian cancer in an Italian case-control study. Cancer Epidemiol Biomarkers Prev 14: 2056-2058.
10. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, et al. (1997) Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci 94: 3290-3295.
11. Duthie SJ, (1999) Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 55: 578-592.
12. Smith AD, Kim YI, Refsum H, (2008) Is folic acid good for everyone? Am J Clin Nutr 87: 517-533.
13. Kim YI, (2008) Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev 17: 2220-2225.
14. Ulrich CM, (2008) Folate and cancer prevention-where to next? Counterpoint. Cancer Epidemiol Biomarkers Prev 17: 2226-2230.
15. Matherly LH, Goldman DI, (2003) Membrane transport of folates. Vitam Horm 66: 403-456.
16. Matherly LH, Hou Z, Deng Y, (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26: 111-128.
17. Ross JF, Chaudhuri PK, Ratnam M, (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73: 2432-2443.
18. Campbell IG, Jones TA, Foulkes WD, Trowsdale J, (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51: 5329-5338.
19. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, et al. (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74: 193-198.
20. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, et al. (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108: 619-626.
21. Ma DW, Finnell RH, Davidson LA, Callaway ES, Spiegelstein O, et al. (2005) Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res 65: 887-897.
22. Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, et al. (2010) Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int J Cancer 127: 21-31.
23. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, et al. (2010) p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A 107: 18622-18627.
24. Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, et al. (2008) Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. Am J Pathol 173: 1165-1172.
25. Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke FE, et al. (2007) Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch 450: 387-395.
26. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, et al. (1999) Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42: 1609-1616.
27. Kelemen LE, (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119: 243-250.
28. Shen DH, Chan KY, Khoo US, Ngan HY, Xue WC, et al. (2005) Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis 26: 855-863.
29. Yang R, Li WW, Hoang BH, Kim H, Banerjee D, et al. (2008) Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 8: 124.
30. Kimura M, Umegaki K, Higuchi M, Thomas P, Fenech M, (2004) Methylenetetrahydrofolate reductase C677T polymorphism, folic acid and riboflavin are important determinants of genome stability in cultured human lymphocytes. J Nutr 134: 48-56.
31. Beetstra S, Salisbury C, Turner J, Altree M, McKinnon R, et al. (2005) Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency. Carcinogenesis [Epub ahead of print].
32. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, et al. (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338: 284-293.
33. Choi SW, Mason JB, (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130: 129-132.
34. Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P, (2001) Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem 276: 39990-40000.
35. Ferreri AJ, Dell'Oro S, Capello D, Ponzoni M, Iuzzolino P, et al. (2004) Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 126: 657-664.
36. Bottero F, Tomassetti A, Canevari S, Miotti S, Menard S, et al. (1993) Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53: 5791-5796.
37. Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, et al. (2003) Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther 10: 1018-1025.
38. Veatch AL, Carson LF, Ramakrishnan S, (1994) Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 58: 393-399.
39. Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, et al. (1997) Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28: 922-928.
40. Miotti S, Tomassetti A, Facetti I, Sanna E, Berno V, et al. (2005) Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol 167: 1411-1427.
41. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, et al. (2008) Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68: 2329-2339.